Phenotypic amikacin resistance may not indicate poor response to amikacin in <i>Mycobacterium avium</i> complex pulmonary disease.

ABSTRACT: When using amikacin to treat Mycobacterium avium complex pulmonary disease (MAC-PD), a minimum inhibitory concentration resistance breakpoint of ≥64 mcg/mL is recommended. We explored whether amikacin resistance characterized by phenotypic drug susceptibility testing was associated with clinical outcomes or mutational resistance in a retrospective cohort of patients with MAC-PD. Despite little aminoglycoside exposure, amikacin resistance was common in our MAC-PD patients but was not associated with worse outcomes or rrs gene mutations.

SUBMITTER: Minuk LM 

PROVIDER: S-EPMC11620508 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature